Key result
Vinpocetine lowers spike-wave index by ~85% in Lennox-Gastaut syndrome case.
Why the study?
Therapeutic options for Lennox-Gastaut syndrome due to GABRB3 mutations are limited, prompting screening for effective compounds.
Case Report (n=1)
Single-blind
No
Answers are grounded in this paper and cite their sources.
Vinpocetine response in one GABRB3 Lennox-Gastaut case is hypothesis-generating; leaves open efficacy in controlled trials.
OBJECTIVE: To screen a library of potential therapeutic compounds for a woman with Lennox-Gastaut syndrome due to a Y302C GABRB3 (c.905A>G) mutation. METHODS: We compared the electrophysiological properties of cells with wild-type or the pathogenic GABRB3 mutation. RESULTS: Among 1320 compounds, multiple candidates enhanced GABRB3 channel conductance in cell models. Vinpocetine, an alkaloid derived from the periwinkle plant with anti-inflammatory properties and the ability to modulate sodium and channel channels, was the lead candidate based on efficacy and safety profile. Vinpocetine was administered as a dietary supplement over 6 months, reaching a dosage of 20 mg three times per day, and resulted in a sustained, dose-dependent reduction in spike-wave discharge frequency on electroencephalograms. Improved language and behavior were reported by family, and improvements in global impression of change surveys were observed by therapists blinded to intervention. SIGNIFICANCE: Vinpocetine has potential efficacy in treating patients with this mutation and possibly other GABRB3 mutations or other forms of epilepsy. Additional studies on pharmacokinetics, potential drug interactions, and safety are needed.
No takes yet. Share an insight, caveat, or question.
Billakota et al. (2019) conducted a case report in Lennox-Gastaut syndrome (n=1). Vinpocetine vs. Baseline was evaluated on Spike-wave index (SWI) on routine EEGs. Vinpocetine administration up to three times daily over 9 months resulted in a sustained reduction in spike-wave index from approximately 20% to 2.9% and improved global clinical function in a patient with Lennox-Gastaut syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: